Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes

Sohag University250 enrolled

Overview

Inherited bone marrow failure syndromes (IBMFSs) are a diverse collection of genetic illnesses characterized by various degrees of peripheral cytopenias due to defective single-lineage or multi-lineage hematopoiesis, it can manifest itself at birth or later in life.

Studying the genetic etiology underlying unclassifiable IBMFSs with bone fragility fractures should be useful for clarifying the undiagnosed pathophysiological mechanisms and other accessory factors to improve the diagnosis, follow-up, prognosis, and management of these patients as well as prevent future complications. Moreover, early diagnosis of risk factors of unusual presentations of IBMFSs will be a useful tool for better treatment strategy. In addition, along with typical IBMFSs, novel clinical entities must be included in an overall molecular portrait of IBMF disorders. As a result, comprehensive genetic analysis will be effective in establishing an accurate genetic diagnosis at medical evaluation.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Inherited BMF Syndrome

Interventions

The whole-exome sequencingGENETIC

Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed a two-generational family with IBMFSs presented with signs and symptoms of bone fragility fractures and admitted or treated in Hematology Division at Internal Medicine Departments of various university hospitals will be screened for enrollment in this study. * The investigators will invite the entire family for testing for IBMFSs mutations, and three additional family members consented to participate in this study. Exclusion Criteria: * • Patients will be diagnosed with paroxysmal nocturnal hemoglobinuria * Patients will be diagnosed with de novo myelodysplastic syndrome * IBMFSs-patients will refuse to consent to this study. * Serologic evidence of recent virus infection as hepatitis A (HAV), HBV, HCV, HEV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), or positive test for HIV. * IBMFSs patients with severe systemic diseases (such as cardiovascular, renal, and hepatic disease) or surgical/medical conditions that might interfere with follow-up instructions. * IBMFs patients with psychiatric disorders or a history of drug abuse,

Locations (1)

, Faculty of Medicine, Sohag University

Sohag, Egypt

RECRUITING

Outcomes

Primary Outcomes

Number of Participants with Progression of pancytopenia

Progression of pancytopenia severity

Time frame: Two year after diagnosis

Number of Participants with Fragility Fractures

occurrence of the Fragility Fractures

Time frame: Two year after diagnosis

Number of Participants with Malignancy transformation

Occurrence of hematological or solid malignancy

Time frame: Two year after diagnosis

Central Contacts

Mahmoud I Elbadry, PhD

CONTACT

+201065964083 mahmoudibrahem837@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.